Triple-antibody therapy targeting HER1-2-3, although previously demonstrated strong tumor control, raises the risk of potential long-term adverse effects such as chronic heart failure [67, 68], given that EGFR, HER2 and HER3 are expressed in myocardium [69, 70]. The gene discussed is ERBB2; the disease is congestive heart failure.